Lilly’s Lantus Rival Sidelined By Safety Concerns
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Lilly will delay regulatory filing plans for its novel long-acting basal insulin peglispro (BIL) until at least after 2016 as it generates additional clinical data to better understand the effect on the liver.